Primary ciliary dyskinesia (PCD), also called immotile ciliary syndrome or Kartagener syndrome, is a rare, ciliopathic, autosomal recessive genetic disorder that causes defects in the action of cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear), fallopian tube, and flagella of sperm cells.
There no standardized effective treatment strategies for the condition. Severe fatal respiratory failure can develop; long-term treatment with macrolides such as clarithromycin, erythromycin and azithromycin has been empirically applied for the treatment of primary ciliary dyskinesia in Japan, though controversial due to the effects of the medications.

Market Analysis and Insights: Global Primary Ciliary Dyskinesia Market
The global Primary Ciliary Dyskinesia market size is projected to reach US$ 638.8 million by 2027, from US$ 429.8 million in 2020, at a CAGR of 5.4% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Primary Ciliary Dyskinesia market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Primary Ciliary Dyskinesia market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Primary Ciliary Dyskinesia market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Primary Ciliary Dyskinesia market.

Global Primary Ciliary Dyskinesia Scope and Market Size
Primary Ciliary Dyskinesia market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Ciliary Dyskinesia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Genetic Testing
Electron Microscopy

Segment by Application
Hospitals
Specialty Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Boehringer Ingelheim
Novartis
Teva
Bayer
Rotech Healthcare
Pfizer